工程化单链可变片段识别肝素诱导血小板减少症中的致病抗体
本研究基于HIT样鼠单克隆抗体KKO,构建野生型及突变型单链可变片段(scFv)库,筛选出5个候选scFv。这些scFv高亲和力结合PF4/肝素复合物,表位与致病抗体重叠,可选择性抑制致病性抗PF4/肝素抗体结合并阻止部分样本血小板活化,而不干扰非致病抗体结合。
要点
- scFv靶向PF4上致病抗体共享结合位点,可区分致病与非致病抗体。
- 候选scFv在血清释放试验中抑制部分HIT样本的血小板活化。
- 该策略有望提高抗PF4/肝素EIA诊断HIT的准确性。
核心结论
- 靶向PF4共享致病区域的scFv可选择性识别致病性抗PF4/肝素抗体,改善HIT诊断准确性。
研究设计与样本
- 基于HIT样鼠单克隆抗体KKO构建野生型scFv,并通过定点突变建立突变体库。
- 经噬菌体生物淘选后根据序列富集筛选出5个候选scFv。
- 用酶免疫分析(EIA)和生物层干涉术验证亲和力与特异性,并用患者血清评估功能。
主要发现
- 5个候选scFv均高亲和力、特异性结合PF4/肝素复合物。
- 表位定位显示KKO与所有scFv结合PF4上重叠的肝素依赖位点。
- scFv选择性抑制致病性抗PF4/肝素HIT抗体结合,并阻止部分样本在血清释放试验中的血小板活化。
- 非致病抗体与PF4/肝素的结合未受干扰。
临床怎么用
- scFv可用于改进抗PF4/肝素EIA,减少非致病抗体导致的假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heparin-induced thrombocytopenia (HIT) is characterized by the production of pathogenic antibodies that bind to complexes of platelet factor 4 (PF4) and heparin, causing platelet activation and a hypercoagulable state. A significant proportion of heparin-treated patients develop nonpathogenic anti-PF4/heparin antibodies that do not activate platelets but interfere with routine screening tests causing frequent false-positive results. We recently showed that pathogenic HIT antibodies are monoclonal and bind to an overlapping PF4 binding site, which could be exploited to identify clinically significant antibodies in patients. This study aimed to develop epitope-specific inhibitors based on the HIT-like murine monoclonal antibody (KKO) that recognizes a binding site overlapping with patient-derived pathogenic HIT antibodies on PF4. We developed a wild-type single-chain variable fragment (scFv) derived from KKO and performed site-directed mutagenesis to create a library of mutant anti-PF4/heparin scFv sequences. Five candidate scFvs were selected based on sequence enrichment after phage biopanning. We confirmed the high affinity and specific binding of these scFv fragments to PF4/heparin complexes using enzyme immunoassays (EIAs) and biolayer interferometry and demonstrated that KKO and all scFvs bind to an overlapping heparin-dependent site on PF4 by epitope mapping. Using patient sera, we demonstrated that our scFv candidates selectively inhibit the binding of pathogenic anti-PF4/heparin HIT antibodies and prevented platelet activation of some samples in the serotonin release assay. Importantly, the binding of nonpathogenic antibodies to PF4/heparin was unperturbed. These findings support the use of scFvs targeting a shared pathogenic region on PF4 to improve the diagnostic accuracy of anti-PF4/heparin EIAs for HIT.
引用
- Bissola AL, Arnold DM, Zhang Y, et al. Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia. Blood. 2026. PMID: 42095961. doi:10.1182/blood.2025031696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。